Norepinephrine + Ascorbic Acid for Cardiovascular Risk

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Cardiovascular Risk+2 MoreNorepinephrine + L-NAME + Ascorbic Acid - Drug
Eligibility
18 - 35
All Sexes
What conditions do you have?
Select

Study Summary

This study is evaluating whether a drug may help improve blood flow in the skin of black individuals.

Eligible Conditions
  • Cardiovascular Risk
  • Vasoconstriction
  • Cardiovascular Disease

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

2 Primary · 0 Secondary · Reporting Duration: Through study completion, an average of 1 Year

Year 1
Role of Oxidative Stress in Heightened Vasoconstriction using Laser Doppler Fluxmetry
Vasoconstrictor Responsiveness to Norepinephrine using Laser Doppler Fluxmetry

Trial Safety

Safety Progress

1 of 3

Trial Design

4 Treatment Groups

Control (Norepinephrine)
1 of 4
Norepinephrine + Ascorbic Acid
1 of 4
Norepinephrine + L-NAME + Ascorbic Acid
1 of 4
Norepinephrine + L-NAME
1 of 4

Active Control

Experimental Treatment

50 Total Participants · 4 Treatment Groups

Primary Treatment: Norepinephrine + Ascorbic Acid · No Placebo Group · Phase 1

Norepinephrine + Ascorbic Acid
Drug
Experimental Group · 1 Intervention: Norepinephrine + Ascorbic Acid · Intervention Types: Drug
Norepinephrine + L-NAME + Ascorbic Acid
Drug
Experimental Group · 1 Intervention: Norepinephrine + L-NAME + Ascorbic Acid · Intervention Types: Drug
Norepinephrine + L-NAME
Drug
Experimental Group · 1 Intervention: Norepinephrine + L-NAME · Intervention Types: Drug
Control (Norepinephrine)
Drug
ActiveComparator Group · 1 Intervention: Control (Norepinephrine) · Intervention Types: Drug

Trial Logistics

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: through study completion, an average of 1 year

Who is running the clinical trial?

The University of Texas at ArlingtonLead Sponsor
25 Previous Clinical Trials
2,363 Total Patients Enrolled
4 Trials studying Cardiovascular Risk
134 Patients Enrolled for Cardiovascular Risk

Eligibility Criteria

Age 18 - 35 · All Participants · 2 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you: